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Nonsense-mediated decay (NMD) is an important process that is best known for degrading transcripts that contain premature stop
codons (PTCs) to mitigate their potentially harmful consequences, although its regulatory role encompasses other classes of transcripts
as well. Despite the critical role of NMD at the cellular level, our knowledge about the consequences of deficiency of its components at
the organismal level is largely limited to model organisms. In this study, we report two consanguineous families in which a similar
pattern of congenital anomalies was found to be most likely caused by homozygous loss-of-function mutations in SMG9, encoding
an essential component of the SURF complex that generates phospho-UPF1, the single most important step in NMD. By knocking
out Smg9 in mice via CRISPR/Cas9, we were able to recapitulate the major features of the SMG9-related multiple congenital anomaly
syndrome we observed in humans. Surprisingly, human cells devoid of SMG9 do not appear to have reduction of PTC-containing
transcripts but do display global transcriptional dysregulation.We conclude that SMG9 is required for normal human andmurine devel-
opment, most likely through a transcriptional regulatory role, the precise nature of which remains to be determined.Introduction
The field of transcriptional regulation has grown rapidly
in the recent past, and completely novel cellular mecha-
nisms, e.g., control of transcript levels by other RNA spe-
cies, have emerged 1. Transcripts destined for translation
have the potential to encode harmful peptides if the
reading frame is altered, a mechanism that underpins
the pathogenesis of many human genetic diseases2,3.
Fortunately, the transcriptional regulatory machinery
has the capacity to address at least some of these errors.
One noteworthy process in this regard is nonsense-medi-
ated decay (NMD). Through NMD, transcripts that
contain a premature stop codon (PTC) are degraded
such that the cell is protected from a potential domi-
nant-negative effect or toxic gain of function exerted by
the truncated protein4–6.
NMD is a complex process that involves RNA-protein
and protein-protein interactions, and it has been observed
in all eukaryotes studied to date6. The current model sug-
gests that exon-exon junctions are flagged by a UPF2-
UPF3B complex (exon junction complex [EJC])7,8. If this
complex is encountered downstream of a stop codon,
this will trigger a series of events. The single most critical
step in this process involves the phosphorylation of
UPF1 by SMG1, a process that requires the dual action of
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[eRF1 and eRF3]) complex, which assembles on ribosomes
that encounter a PTC9. Upon its phosphorylation, UPF1 re-
leases eRF1 and eRF3, recruits SMG5, SMG6, and SMG7
and halts translation. SMG5–SMG7-mediated exonucleo-
lytic decay and SMG6-mediated endonucleolytic decay
lead to degradation of the PTC-containing transcript10–15.
It is worth highlighting that NMD also operates in a
partially redundant EJC-independent manner15,16.
Importantly, NMD also acts on ‘‘physiological’’ tran-
scripts, and at least 10% of human transcripts are subject
to NMD regulation17–19. These transcripts are not limited
to those harboring PTCs introduced normally through
alternative splicing, but also include transcripts with a
multitude of other features, including those in which the
normal stop codon is separated from the poly(A)-binding
protein by a long 30 UTR, those with a 30 UTR that spans
an intron, and those with an upstream open reading
frame20–23.
The consequences of deficiency of NMD components in
humans in the developmental context are largely un-
known, with the exception of UPF3B (MIM: 300298),
loss-of-function mutations of which result in intellectual
disability (MIM: 300676) 23. In this study, we show that
deficiency of another NMD component, SMG9, although
compatible with embryonic viability, is associated with a
number of major malformations.Riyadh 11211, Saudi Arabia; 2Department of Genetics, Hamad Medical Cor-
yadh 12625, Saudi Arabia; 4Department of Biostatistics, Epidemiology, and
adh 11211, Saudi Arabia; 5The Jackson Laboratory, Bar Harbor, ME 04609,
l University, Riyadh 11533, Saudi Arabia
.A.)
erican Journal of Human Genetics 98, 643–652, April 7, 2016 643
Materials and Methods
Human Subjects
Affected individuals were phenotyped via standard clinical evalu-
ation, including appropriate imaging and laboratory tests. All
available family members were recruited after they gave informed
consent and were enrolled in an institutional review board (IRB)-
approved research protocol (KFSHRC RAC no. 2080006). Blood
was collected in EDTA tubes for DNA extraction and in Na-heparin
tubes for the establishment of lymphoblastoid cell lines.
Autozygome Mapping and Linkage Analysis
We determined the entire set of autozygosity intervals per genome
(autozygome) as described before24,25. In brief, runs of homozy-
gosity (ROH) R2 Mb in size, used as surrogates of autozygosity,
were determined from genome-wide SNP genotypes obtained on
the Axiom SNP Chip platform (Affymetrix) via AutoSNPa26. We
performed linkage analysis with the GeneHunter multipoint link-
age analysis algorithm by employing a fully penetrant autosomal-
recessive model27.
Exome Sequencing
Exome capture was performed with a TruSeq Exome Enrichment
kit (Illumina) according to the manufacturer’s protocol. Samples
were prepared as an Illumina sequencing library, and in the second
step, the sequencing libraries were enriched for the desired target
with the Illumina Exome Enrichment protocol. The captured li-
braries were sequenced with an Illumina HiSeq 2000 Sequencer.
The reads were mapped by the Burrows-Wheeler Aligner against
the UCSC Genome Browser hg19 reference genome. The SNPs
and indels were detected by SAMtools. Variants from whole-
exome sequencing were filtered such that only novel or very low
frequency (0.1%) coding or splicing homozygous variants within
the shared autozygome of the three affected individuals were
considered as likely causal variants. The frequency of variants
was determined via publicly available variant databases (1000
Genomes, the Exome Variant Server, and the Exome Aggregation
Consortium [ExAC] Browser), as well as a database of 734 in-house
ethnically-matched exomes.
Real-Time RT-PCR and Immunoblotting
For RT-PCR and relative qRT-PCR, total RNA from affected-individ-
ual and control-individual lymphoblastoid cell lines was extracted
with the QIAamp RNAMini Kit (QIAGEN), and DNase was treated
by the RNase-Free DNase Set (QIAGEN), according to themanufac-
turer’s recommendations. Preparation of the cDNAwas carried out
with the iScriptTM cDNA synthesis kit and Poly T oligonucleotide
primers (Applied Biosystems). Two sets of primers for SMG9 (MIM:
613176) cDNA were designed to specifically amplify the cDNA
(SMG9 exons 5–7 and 5–8). Relative qRT-PCR for the expression
of SMG9, VIM (MIM: 193060), TNS3 (MIM: 606825), EGR1
(MIM: 128990), UCHL1 (MIM: 191342), SPINT2 (MIM: 605124),
RORA (MIM: 600825), and VCAN (MIM: 118661) was performed
with SYBR Green and an Applied Biosystems 7500 Fast Real-
Time PCR System (Table S3).
For immunoblotting, total protein was extracted from one
affected-individual and three control-individual lymphoblastoid
cells. Anti-SMG9 antibody was purchased from Sigma Aldrich
(SAB2107730). The membrane was blocked with 5% milk powder
in PBS with Tween for 1 hr at room temperature (RT) and incu-
bated with the primary antibody (dilution 1/500) overnight at644 The American Journal of Human Genetics 98, 643–652, April 7, 24C, followed by stringency washes and treatment with secondary
antibody for signal detection.Global Transcriptional Profiling and Statistical
Analysis
Lymphoblastoid cells from one affected individual and three
healthy control individuals (two females and one male, age range
2–6 years) were used for global expression profiling, performed in
triplicate for each sample, via Affymetrix’s GeneChip Human
Genome U133 Plus 2.0 Arrays. Sample handling, cDNA synthesis,
cRNA labeling and synthesis, hybridization, washing and scan-
ning of chips, and all related quality controls were performed ac-
cording to the manufacturer’s instructions. In brief, a total of
200 ng of RNAwas reverse transcribed to synthesize the first strand
of cDNA with the help of oligo-dT primers containing T7 flanking
sequence. After second-strand synthesis, in vitro transcription was
carried out with labeled aRNA. After purification and fragmenta-
tion of aRNA, the samples were hybridized overnight onto U133
Plus 2.0 Arrays. Finally, after being washed to remove the unbound
transcripts, the hybridized microarrays were scanned and the in-
tensity (CEL) files with the acquisition and initial quantification
of array images were generated with Expression Console 1.3.
Significantly modulated genes were defined as those with absolute
fold change (FC) > 2 and adjusted p value < 0.05. We used the
Benjamini-Hochberg step-up procedure to control the false discov-
ery rate (FDR) at 5% 28. Functional pathway, gene ontology (GO),
and network analyses were performed with Ingenuity Pathways
Analysis (IPA) 6.3 (Ingenuity Systems) and DAVID Bioinformatics
Resources29. A right-tailed Fisher’s exact test was used to calculate a
p value determining the probability that the biological function
(or pathway) assigned to that dataset is explained by chance alone.
For GO analysis, we used the background list of genes expressed in
lymphoblastoid cell lines that was obtained from The Gene
Expression Barcode project. Statistical analyses were performed
with the MATLAB software packages (Mathworks) and Partek Ge-
nomics Suite. P values were calculated via two-sided tests. P values
of less than 0.05 were considered statistically significant.Generation of Smg9/ Mice
A null mutation was generated in mouse Smg9 via CRISPR/Cas9
mutagenesis. A guide RNA was designed against exon 2 (first cod-
ing exon) with the online tool CRISPR Design, and a single guide
with minimal off-target potential and sequence TCTACGGGATA
GAGCGGCGGwas selected. Production of sgRNA andmicroinjec-
tion was performed as previously described30. In brief, an oligonu-
cleotide that includes a T7 promoter and the guide sequence above
is annealed to a reverse primer that includes the entire stem-loop
sequence and is amplified by PCR. The resulting PCR products
were in vitro transcribed and purified, and the quality of the
RNA products was confirmed with an Agilent Bioanalyzer 2100.
All animal procedures were conducted according to relevant na-
tional and international guidelines (AALAC and IACUC) and have
been approved by The Jackson Laboratory animal care and use
committee (protocol no. 99066). C57BL/6NJ and CB6F1/J mouse
strains were used as embryo donors and pseudopregnant recipient
dams, respectively. Cas9 mRNA (100 ng/ml) (TriLink Biotechnol-
ogies) and sgRNA (50 ng/ml) were injected into the pronuclei of
zygotes. Oviduct transfers into pseudopregnant dams were
performed on the same day. Founder mice were screened by PCR
and Sanger sequencing, identifying several putative mutants.
A single allele was chosen for expansion and analysis, which was016
Figure 1. Identification of an Autosomal-Recessive Multiple Congenital Anomalies Syndrome
(A) Pedigrees of the two study families showing the consanguineous nature of the parents. The index individual is indicated in each
pedigree by an arrow, and asterisks denote individuals whose DNA was available for analysis.
(B) CT scan for the index individual in family 1 (IV:5) showing cerebellar vermis hypoplasia.
(C andD) Facial images of the index individual in family 2 (V:1) showing a right-sided cleft lip (status post repair), a full and everted lower
lip, a widow’s peak, hypertelorism, small eyes, posteriorly rotated ears with attached lobules, and a broad nasal bridge.confirmed by TOPO TA cloning and sequencing (Life Technolo-
gies). Genotyping protocols and mice are available at The Jackson
Laboratory mouse strain datasheet.
To produce homozygous embryos, timed matings were per-
formed, where day ‘‘0’’ was assumed to be the midpoint of the
prior light cycle after the appearance of a copulation plug. Dissec-
tions were performed at the time indicated. Embryos were photo-
graphed, fixed in 4% paraformaldehyde (24 hr for embryonic day
15.5 [E15.5] and 48 hr for E18.5), stabilized in an acrylamide-based
hydrogel31, and stained in Lugol’s solution (Sigma catalog no.
L6146-1L) for 24 hr (E15.5) or 48 hr (E18.5). Samples were then
rinsed with 13 PBS and embedded in 1% agarose for imaging.
Imaging was conducted on a Bruker Skyscan 1172 X-ray scanner
(Bruker BioSpin). Images were reconstructed with NRecon soft-
ware (Bruker BioSpin) and surface rendered with Imaris software
(Bitplane).
For the qRT-PCR of Smg9, RNAwas purified from E15 embryonic
tissue. Isolated RNA was subject to DNA degradation. cDNA was
generated with a High Capacity RNA-to-cDNA Kit (Applied Bio-
systems), followed by RNA degradation. A TaqMan (Applied Bio-
systems) assay was designed to amplify cDNA for Smg9 transcripts.
Primers were designed to span the exon 2 and exon 3 junction
with the probe lying directly over the exon 2 and exon 3 junction
site to eliminate genomic DNA amplification. Smg9 qPCR was
performed with Applied Biosystems TaqMan reagents, and Gapdh
was used as the internal control, multiplexed to optimize accuracy.The AmTaqMan assay was amplified via conditions specified by Applied
Biosystems. We used a reaction volume of 10 ml containing
40 ng cDNA. Thermocycler conditions included an initial hold
at 50 for 2 min, polymerase activation hold at 95 for 20 s, 40
cycles of 95, a 1 s denaturation, and a 20 s 60 anneal and exten-
sion time. The analysis was performed with Viia7 analysis soft-
ware. Samples were run in triplicate. Wild-type expression was
calculated with n ¼ 1. Each biological replicate is represented on
the bar graphs.Results
Clinical Report
The proband in family 1(IV:5) is a Saudi Arabian female
delivered at term by elective cesarean section to a
33-year-old gravida 12, para 8 mother with history of three
abortions. The parents are first-degree cousins (Figure 1A).
One sibling died at the age of one year and had multiple
congenital anomalies similar to the proband’s, as well as
a cleft palate (no records available). There is history of a
stillborn girl who also had a similar pattern of multiple
congenital anomalies (no records available). She was found
to have craniofacial dysmorphism, microphthalmia, and
major brain and heart malformations and died at 7 weekserican Journal of Human Genetics 98, 643–652, April 7, 2016 645
Table 1. Clinical Details of the Three Affected Individuals Recruited in this Study
Category Subcategory Features
Family 1, IV:5 family history – parents are 1st degree cousins, one sibling who had died at the age of one year with a
similar disease
head and neck head prominent forehead and occiput
ears low set malformed ears
eyes microphthalmia
nose depressed nasal bridge and anteverted nares
mouth high arched palate
skeletal hands clenched hands with camptodactyly
neurologic CNS Dandy-Walker malformation, cerebellar vermis hypoplasia, hypoplastic corpus
callosum
cardiovascular heart interrupted aortic arch, hypoplastic tricuspid and aortic valves, large muscular VSD
Family 2, V:1 family history – parents are 1st degree cousins, one similarly affected cousin
head and neck head narrow forehead
ears posteriorly rotated ears with attached lobules
eyes hypertelorism and poor vision
nose broad nasal bridge
mouth full and everted lower lip, right-sided cleft lip
skeletal hands syndactyly between 2nd and 3rd toes
neurologic – Dandy-Walker malformation, decreased myelination, brain atrophy
cardiovascular heart large VSD
Family 2, IV:3 head and neck head NA
skeletal hands NA
neurologic – truncal hypotonia with peripheral hypertonia, brisk deep tendon reflexes, adductor
spasm in both lower limbs
cardiovascular heart VSD
Abbreviations are as follows: NA, not available; VSD, ventricular septal defect.of age. Family 2 consists of first-cousin healthy parents of
Qatari origin with one child (index, V:1) and a first cousin
(IV:3) who was also found to have a similar phenotype in
the form of craniofacial dysmorphism, congenital heart
disease, and brain malformation (Figure 1A). For clinical
details of the three affected individuals, see the Supple-
mental Note and Table 1.
A Multiple Congenital Anomaly Syndrome Is Linked
to Loss-of-Function Mutations in SMG9
The phenotypic overlap (especially the Dandy-Walker mal-
formation and congenital heart disease) between the
affected members of both families, their consanguineous
nature, and different geographic origin in Arabia prompted
us to consider the possibility that the disease is caused by
homozygosity for two distinct founder haplotypes (one
in family 1 and another in family 2) that harbor patho-
genic variants in the same gene. Indeed, the autozygome
of the three affected individuals overlapped on a single lo-
cus in which the two families displayed two different hap-
lotypes, and this was further confirmed by linkage analysis646 The American Journal of Human Genetics 98, 643–652, April 7, 2(Figure 2A and Figure S1). To identify the likely causal
variant within this critical locus, we performed exome
sequencing on each of the two probands and achieved
803 mean depth of the target region (target was 52 Mb),
and 97% of target regions were covered with at least 103
depth. We only considered homozygous coding and
splicing novel variants within the critical locus
(Figure S2). Only one variant per exome remained
(c.520_521delCC and c.701þ4A>G) according to these fil-
ters, both affecting the same gene, SMG9 (GenBank:
NM_019108.2). Sanger sequencing confirmed homozygos-
ity for these mutations in the probands and heterozygosity
in the parents (Figure 2B). The indel in family 1 predicts a
frameshift and premature truncation, p.Pro174Argfs*12.
Splice Site Prediction by Neural Network indicates that
the intronic variant in family 2 reduces the score of the
consensus donor site of exon 6 from 0.98 to 0.65. However,
RT-PCR on lymphoblastoid cells from the index individual
in family 2 revealed complete skipping of exon 6. The
resulting aberrant transcript that predicts frameshift and
premature truncation (p.Tyr197Aspfs*10) was the only016
Figure 2. A Multiple Congenital Anomalies Syndrome Is Linked to SMG9 Mutations
(A) AgileMultiIdeogram showing a single homozygous region, on chromosome 19, shared between the three affected individuals from
the two families as indicated by the dark blue bars boxed in red.
(B) Upper panel: schematic representation of SMG9 transcript (red triangles indicate the sites of the two mutations). Lower panel:
sequence chromatograms of two variants in SMG9 identified in the family (control tracing is shown for comparison and the location
of the mutation is denoted by red stars).
(C) RT-PCR gel image and sequence chromatogram show the enhancement of aberrant SMG9 transcript in lymphoblasts derived from
affected individual (Aff) as comparedwith lymphoblasts from a healthy individual of similar age (control), and the absence of the normal
SMG9 transcript.
(D) Relative quantitative real-time PCR showing 50% reduction in SMG9 expression in the affected individual in comparison to expres-
sion in the control individual. Result is the average for three independent experiments and three control individuals (p< 0.03 on t test).
(E) Immunoblotting with antibody against the N terminal of SMG9 (SAB2107730) showing no detectable band from cells derived from
the index individual (Aff) (target mass KDa, 57.7, 54.8) as compared with those derived from the three normal control individuals (Ct1,
Ct2, Ct3), as well as the absence of the truncated SMG9 isoform at 22 KDa.recovered transcript in the affected individual, unlike con-
trol individuals, who possessed this band at a very low
abundance in comparison to the normal exon-6-contain-
ing transcript (Figure 2C). Western blot analysis revealed
complete lack of SMG9, and the predicted truncated iso-
form could not be recovered, indicating NMD and/or insta-
bility (Figure 2E and Figure S3). Indeed, qRT-PCR showed
50% reduction of the SMG9 transcript, as compared to con-
trol individuals (p < 0.03) (Figure 2D). Taken together, our
results are consistent with SMG9 deficiency as the likely
cause of the multiple congenital anomaly syndrome we
observed in the two probands.
No Evidence of Widespread Perturbation of NMD in
SMG9 Deficiency
SMG9 has been found to be necessary for SMG1-mediated
phosphorylation of UPF1, the single most important step
in NMD, so we were surprised by the finding that the in-The Amdex individual in family 2 (V:1), who appears to have
complete deficiency of SMG9, shows evidence of NMD
of the PTC-containing SMG9 transcript (Figure 2D). There-
fore, we set out to test the entire transcriptional profile of
the affected individual and compare it to that of control
individuals for whom exome sequencing data were avail-
able. We first looked for evidence in control individuals
that transcripts with PTC are significantly lower than
other transcripts in general and found that, despite
extreme variability, such was the case (p < 0.01). We
then repeated the same test on the affected individual
and found that the same pattern was observed
(Figure S4 and Table S1). Comparing the expression of
27 common PTC-containing genes in control individuals
and in the affected individual revealed no significant
difference (p value > 0.05) (Figure S5 and Table S2). How-
ever, as shown in Figure 3, the global transcriptional pro-
file of the affected individual and control individualserican Journal of Human Genetics 98, 643–652, April 7, 2016 647
Figure 3. Global Transcriptional Changes Associated with SMG9 Deficiency
(A) Heat-map of genes that were significantly dysregulated in a SMG9-deficient individual in comparison to three control individuals.
The hierarchical clustering clearly distinguished individuals as either affected or controls. The expression level of each gene across the
samples is scaled to [-3, 3] interval. These mapped expression levels are depicted with a color scale as shown at the bottom of the figure,
such that highly expressed genes are indicated in red, intermediate in black, and weakly expressed in green.
(B) GO and functional analysis of DE genes (up- or downregulated). x axis indicates the significance (log p value) of the functional
association that is dependent on the number of genes in a class as well as biological relevance. Dark bars represent upregulated genes,
and light bars represent downregulated genes. The threshold line represents a p value of 0.05.revealed a pattern of gene dysregulation that clearly
distinguished individuals as either affected or controls
(Figure 3A). We observed a prevalent upregulation of
gene expression as a result of SMG9 deficiency. Indeed,
with a stringent statistical threshold (FDR of 5% and
FC > 2), 300 probes were differentially expressed (DE),
of which 238 probes (171 genes) were upregulated and
62 probes (54 genes) were downregulated, when
comparing expression in the affected individual versus
that in the control individuals (Figure 3A and Table S1).
Validation was carried out on selected genes taken from
the most dysregulated ones by quantitative real-time
PCR, and the results were in agreement with the microar-
ray (Figure S6). The GO and functional analyses of upre-
gulated DE genes showed an over-representation of genes
involved in cellular movement, development, growth and
proliferation, immune response, and cell death. On the
other hand, lipid metabolism and the tissue development
process were significantly enriched categories among the
downregulated genes (Figure 3B). Although we cannot
exclude the possibility of an effect by SMG9 deficiency
on NMD for specific transcripts, our data suggest that
there is no widespread impairment of NMD although
the transcriptional profile was dysregulated.648 The American Journal of Human Genetics 98, 643–652, April 7, 2Smg9/ Mice Have Reduced Viability and Display
Major Brain, Eye, and Cardiovascular Malformations
To determine its role in amammalianmodel, we attempted
to generate a null allele of Smg9 in the mouse by using
CRISPR/Cas9. We targeted exon 2 (first coding exon) of
Smg9 by using a single guide sequence designed to mini-
mize off-target potential. From eight founders, a single mu-
tation containing a combination of a 2 bp deletion and
10 bp insertion (Figures 4A and 4B) was chosen for expan-
sion and analysis. This mutation is predicted to result in a
frameshift and a premature stop at amino acid position
104 (Figure 4C). qRT-PCR on E15.5 embryos showed that
Smg9 is reduced by 60%–80%, indicating that the mouse
line is at least a severe hypomorph (Figure S7).
Intercrosses of heterozygous animals yieldednohomozy-
gous pups, suggesting embryonic lethality. To identify and
characterize embryonic phenotypes of Smg9/, we per-
formed timed matings and harvested embryos at E14.5,
E15.5, andE18.5 (Table 2). As shown in Figure 5 andTable 2,
phenotypes were identified at all stages, and the exact pre-
sentation varied significantly between specimens. For
example, homozygous embryos examined at E15.5 showed
a range of phenotypes including edema, hemorrhage,
and exencephaly (Figures 5C and 5D) and in one case,016
Figure 4. Generation of an Smg9 Null Allele
(A) Schematic of mouse Smg9, showing the position of the CRISPR guide position in exon 2 (first coding exon; exon numbers indicated
above the gene model). The mutant allele chosen for analysis contains a 2 bp deletion and simultaneous 10 bp insertion, resulting in a
frameshift mutation beginning at 7:24403443 (GRCm38/mm10).
(B) Sequence chromatogram of a TOPO-TA clone of the mutant allele (top) and a heterozygous mutant (bottom), confirming the allele
structure. Red box indicates inserted sequence.
(C) Structure of the predicted protein product showing the frameshift at residue 16 and the predicted premature termination at position
104. The aligned human protein is shown above the mouse sequence.
(D) SMG9 phylogenetic tree and conservation across species.hind-limb preaxial polydactyly (Figure 5D, arrow). These
phenotypes are variable and incompletely penetrant, but
the majority of homozygotes display some clear pheno-
typic abnormality, unlike wild-type and heterozygous em-
bryos (Figures 5A and 5B). To examine these phenotypes
in more detail, we performed iodine-contrast microCT
(computed tomography), which provides a high-resolution
3Ddatasetwith sufficient contrast to observe internal struc-
tures. Mutant embryos were clearly smaller and develop-
mentally delayed. Several other features were noted,
including edema, observed during gross inspection (Figures
5H–5J, arrowheads).We also noted reduced size in themid-
and hindbrain relative to their stage of development
(Figure 5H),microphthalmia (Figure 5I), thinmyocardium,
and a very prominent atrioventricular septal defect (AVSD)
(Figure 5J, arrow). At E18.5, the twohomozygotes identified
displayed variable levels of edema (Figures 5L and 5M),
with evidence of hemorrhage. One specimen was deadTable 2. Summary of Genotypes and Phenotypes Observed in Smg9 M
Stage (n)
Genotype Mutant Phenotypes
þ/þ /þ / Developmental Delay B
E14.5 (4) 1 1 2 2/2 2
E15.5 (38) 13 17 8 8/8 7
E18.5 (13) 6 5 2 2/2 2
NA, not applicable.
The Am(Figure 5M) and showed thin myocardium in sections of
microCT volumes (Figure 5S, arrow) and anophthamia (Fig-
ures 5M and 5R, arrow) of one eye, consistent with the phe-
notypes observed at E15.5. Thus, our findings support a role
for Smg9 in brain, heart, and eye development.Discussion
The widespread role of NMD in transcriptional regulation
suggests that defects in NMD can have pathological
consequences at the organismal level. Interrogating a
developmental role of NMD is challenging because
many of its components have additional physiological
roles. Moreover, NMD, although conserved across eukary-
otes as a mechanism, differs in its details between
different species such that the results observed in one
species are not necessarily applicable to others6,32.ouse Embryos
rain (uCT) Edema Heart (uCT) Eye (uCT) Limb
/2 2/2 NA NA 1/4
/7 7/8 7/7 7/7 1/8
/2 1/2 1/2 1/2 0/2
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Figure 5. Multiple Developmental Abnormalities in Smg9/ Mouse Embryos
(A–D) Mutant embryos at E15.5 display multiple developmental defects, including exencephaly (C) and sporadic hemorrhage and
edema (D), versus wild-type (A) or heterozygous (B) littermates.
(E–J) Volume slices of iodine-contrast microCT images of the mutant in (D) show multiple defects, including abnormal brain develop-
ment (arrow, H), microphthalmia (arrow, I), and an atrioventricular septal defect and thin myocardium (arrow, J). Clear edema in the
mutant images is indicated by the arrowheads (H–J). Control E15.5 sections from similar planes are shown in (E)–(G).
(K–S) Some embryos survived or were recovered dead at E18.5 (L andM versus K). As with earlier stages, bothmutants were developmen-
tally delayed and showed a variable degree of edema. One mutant had anophthalmia of one eye (arrow in M and R). MicroCT images of
the mutant in (M) show edema (arrowheads in R and S), a severely malformed brain (Q), and abnormally thin myocardium in (S). Con-
trol sections through similar planes are shown in (N)–(P).
Scale bars for (E)–(J) are 0.5 mm (E and H) and 1.0 mm (F, G, I, and J) and for (N)–(S) are 1.0 mm (N, O, Q, and R) and 2.0 mm (P and S).Nonetheless, reduced embryonic viability as a converging
phenotype among animal models deficient for at least
some components of NMD appears to suggest that
NMD does contribute to normal development. For
example, knockdown of SMGL-1 and SMGL-2 is embry-
onically lethal in C. elegans33. In fruitflies, depletion of
UPF1 and UPF2 is also embryonically lethal34. Zebrafish
morphants for upf1, upf2, smg5, or smg6 have high rates
of embryonic lethality35. Finally, mice knocked out for
Smg1, Upf1, or Upf2 display early embryonic lethality as
well 36–38.
SMG9 was first identified as a component of NMD in
2009 when it was found, along with SMG8, to co-purify
with SMG1, forming a stable SMG1-SMG8-SMG9 com-
plex11. Further characterization of this protein revealed
that it is part of the SURF complex and is necessary for
the phosphorylation of UFP1 by SMG1. Deletion mapping
identified that the presence of both N and C termini is
needed for the proper binding to SMG139. Although the
consequences of SMG9 deficiency on the NMDmachinery
are clearly demonstrated, virtually nothing is known about650 The American Journal of Human Genetics 98, 643–652, April 7, 2its developmental relevance. As mentioned above, defi-
ciency of various NMD components has been found to
result in abnormal development in model organisms,
and UPF3B deficiency in humans is linked to intellectual
disability40. However, SMG9 deficiency states have not
been established in humans or other model organisms.
Our study, therefore, fills an important gap in our knowl-
edge of the developmental role of this component
of NMD.
The identification of a single disease locus and two inde-
pendent, homozygous, apparently loss-of-function muta-
tions therein involving the same gene is highly suggestive
of a causal relationship between SMG9 mutations and the
multiple congenital anomaly syndrome we describe. This
is further corroborated by the recapitulation of key devel-
opmental defects in the knockout mice we generated via
CRISPR/Cas9 mutagenesis in this study. Interestingly, the
predominant involvement of the brain is reminiscent of
the zebrafish morphants that are knocked down for
various NMD components in which the hindbrain is
particularly affected 35. However, the mechanism through016
which SMG9 deficiency results in abnormal embryogen-
esis remains unclear.
Perturbation of NMD was a prime candidate mecha-
nism in view of the established role of NMD in protect-
ing the cells from the toxic effect of PTC-containing
proteins. However, our finding that the SMG9 mutant
transcript itself is subject to NMD in the affected individ-
ual’s cells suggested to us that this might not be the case.
Indeed, subsequent global transcriptional profiling also
failed to show evidence of impaired NMD as a result of
SMG9 deficiency. Although different transcripts are
known to have different sensitivity to NMD, so we
cannot exclude the possibility that NMD is defective
for certain PTC-containing transcripts, our data suggest
that NMD was generally functional. Given that NMD af-
fects at least 10% of human transcripts, many of which
lack PTC, it is possible that the generalized transcrip-
tional dysregulation we observed is still reflective of an
abnormality in NMD that we could not measure. Inter-
estingly, it has been suggested that SMG9 might play
other physiological roles independent of its role in
NMD because it was identified in homodimers that are
not part of the SURF complex, and this could also be
relevant to the transcriptional dysregulation of affected
individuals’ cells39.
In conclusion, this study shows that SMG9 mutations
most likely cause a distinctive multiple congenital anom-
aly syndrome in humans and that its deficiency in mice
also leads to abnormal embryogenesis and an overlapping
developmental profile. Despite the established role of
SMG9 in NMD, we show that PTC-containing transcripts
do undergo efficient degradation in the context of SMG9
deficiency, although the latter state is still associated with
widespread transcriptional dysregulation. Future studies
will be needed to further delineate SMG9-related pheno-
types in humans and the underlying mechanism, which
might be related to a non-NMD role played by this
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